Introduction TKIs are paradigmatic in CML management and offer patients the prospect of a
normal life expectancy. As a consequence, the focus of both the clinician and patient has …

Tyrosine kinase inhibitors (TKI) have improved the outcome and life expectancy of patients
with chronic myeloid leukemia (CML). Patients are diagnosed with CML at younger ages …

The management of chronic myeloid leukemia (CML) diagnosed during pregnancy is a rare
and challenging situation. We report the treatment and outcome of 87 cases diagnosed in …

Since the introduction of tyrosine kinase inhibitors (TKIs) at the beginning of the millennium,
the outlook for patients with chronic myeloid leukemia (CML) has improved remarkably. As …

Chronic myeloid leukemia (CML) management during pregnancy is challenging. In this
retrospective study, hospital records of CML patients treated between 2000 and 2021 were …

Nilotinib is a second‐generation BCR‐ABL tyrosine kinase inhibitor for the treatment of
Philadelphia chromosome‐positive chronic myeloid leukemia in both adult and pediatric …

ABSTRACT Introduction Tyrosine kinase inhibitors (TKIs) have revolutionized survival rates
of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute …

Cancers affecting pregnant women include breast cancer, melanoma, thyroid cancer,
cervical cancer, lymphomas, and leukemias. The medical management of cancer during …

Chronic myeloid leukemia (CML) has evolved from an invariably fatal disease to a chronic
disorder that can be treated with targeted drugs and allows survival expectations …

Leukemia may rarely develop in a woman during pregnancy, posing clinical challenges to
the patient, fetus, family, and medical staff managing malignancy and pregnancy. We …